Jennifer Mak Sells 1,134 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc (NASDAQ:AXON) CAO Jennifer Mak sold 1,134 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $600.00, for a total transaction of $680,400.00. Following the completion of the sale, the chief accounting officer owned 13,740 shares in the company, valued at approximately $8,244,000. This trade represents a 7.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Axon Enterprise Price Performance

AXON stock opened at $591.15 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. The firm has a 50 day moving average price of $602.67 and a 200-day moving average price of $703.63. Axon Enterprise, Inc has a 52-week low of $469.24 and a 52-week high of $885.91. The firm has a market capitalization of $46.65 billion, a price-to-earnings ratio of 187.07, a PEG ratio of 135.74 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The company had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. During the same period last year, the business earned $1.45 EPS. The firm’s quarterly revenue was up 30.6% on a year-over-year basis. Equities research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Axon Enterprise

Hedge funds have recently added to or reduced their stakes in the stock. Allworth Financial LP grew its holdings in shares of Axon Enterprise by 1.0% in the third quarter. Allworth Financial LP now owns 5,792 shares of the biotechnology company’s stock worth $4,156,000 after acquiring an additional 58 shares during the period. Swiss Life Asset Management Ltd boosted its position in Axon Enterprise by 23.5% in the third quarter. Swiss Life Asset Management Ltd now owns 14,153 shares of the biotechnology company’s stock worth $10,157,000 after purchasing an additional 2,694 shares during the last quarter. Strategic Advocates LLC grew its stake in shares of Axon Enterprise by 1.2% during the 3rd quarter. Strategic Advocates LLC now owns 1,856 shares of the biotechnology company’s stock valued at $1,332,000 after purchasing an additional 22 shares during the period. CIBC Private Wealth Group LLC grew its stake in shares of Axon Enterprise by 26.4% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 186,538 shares of the biotechnology company’s stock valued at $133,867,000 after purchasing an additional 38,966 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Axon Enterprise during the 3rd quarter valued at about $9,718,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Morgan Stanley reduced their price objective on shares of Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday. JMP Securities restated a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a report on Monday, September 29th. UBS Group lowered their price objective on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $870.00 target price on shares of Axon Enterprise in a report on Wednesday, September 24th. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $802.71.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.